Table II.
Comparison of the median age of patients with COVID-19–associated skin manifestations (n = 187)∗
| Analyzed parameters | Median (IQR) | P value |
|---|---|---|
| Cutaneous phenotypes | ||
| Urticarial rash | ||
| Yes (n = 19) | 54 (36-58) | .1663 |
| No (n = 168) | 57.5 (41-74) | |
| Confluent erythematous/maculopapular/morbilliform rash | ||
| Yes (n = 48) | 61 (51.5-78) | .029 |
| No (n = 159) | 55 (36-71) | |
| Papulovesicular exanthem | ||
| Yes (n = 29) | 57 (44-75) | .4863 |
| No (n = 158) | 57 (40-73) | |
| Chilblain-like acral pattern | ||
| Yes (n = 46) | 38.5 (23-55) | <.0001 |
| No (n = 141) | 60 (50-75) | |
| Livedo reticularis/racemosa-like and purpuric vasculitic pattern | ||
| Yes (n = 17) | 66 (58-84) | .0022 |
| No (n = 170) | 55 (39-71) | |
| Disease severity | ||
| Asymptomatic status and mild COVID-19 (n = 75) | 40 (27-57) | <.0001 |
| Moderate and severe COVID-19 (n = 112) | 64 (54.5-78) | |
| Systemic symptoms | ||
| Fever | ||
| Yes (n = 136) | 59 (50-75) | <.0001 |
| No (n = 51) | 38 (26-61) | |
| Cough | ||
| Yes (n = 102) | 58.5 (50-74) | .0077 |
| No (n = 85) | 52 (30-71) | |
| Dyspnea | ||
| Yes (n = 71) | 65 (55-78) | <.0001 |
| No (n = 116) | 49 (30.5-63) | |
| Pneumonia | ||
| Yes (n = 101) | 65 (55-80) | <.0001 |
| No (n = 86) | 41.5 (28-57) | |
| Hyposmia/hypogeusia | ||
| Yes (n = 41) | 55 (44-65) | .3337 |
| No (n = 146) | 57.5 (40-75) | |
| Gastrointestinal symptoms | ||
| Yes (n = 43) | 55 (44-71) | .9462 |
| No (n = 144) | 57 (38.5-73.5) |
IQR, Interquartile range.
∗
Patients with more than 1 cutaneous phenotype were excluded from the statistical analysis.